Simple blood test could replace biopsies for kidney transplant patients

NCT ID NCT07551531

Not yet recruiting Diagnosis Sponsor: Insight Molecular Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study will test a new blood test called GraftAssure that measures DNA from the donor kidney in the recipient's blood. The goal is to see if this test can detect rejection more accurately than current methods. Researchers will enroll 5,000 kidney transplant patients and follow them over time. If the test works well, it could help doctors catch rejection earlier and avoid some invasive biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GraftAssure blood test (measures donor-derived cell-free DNA)
What this could lead to: If successful, this test could help doctors detect kidney rejection earlier and more accurately, potentially reducing the need for invasive biopsies.
What could go wrong: This is an observational registry study, not a treatment trial. The test may not prove superior to existing methods, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rejection, Psychology

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT

Contacts and locations

Locations

Cooperman Barnabas Medical Center

Livingston, New Jersey, 07039, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.